Unique ID issued by UMIN | UMIN000044807 |
---|---|
Receipt number | R000050181 |
Scientific Title | Prospective observation study for combination therapy of Docetaxel and Ramucirumab after immunochemotherapy in advanced non-small cell lung cancer patients |
Date of disclosure of the study information | 2021/07/09 |
Last modified on | 2023/04/26 18:48:16 |
Prospective observation study for combination therapy of Docetaxel and Ramucirumab after immunochemotherapy in advanced non-small cell lung cancer patients
Prospective observation study for combination therapy of Docetaxel and Ramucirumab after immunochemotherapy in advanced non-small cell lung cancer patients
Prospective observation study for combination therapy of Docetaxel and Ramucirumab after immunochemotherapy in advanced non-small cell lung cancer patients
Prospective observation study for combination therapy of Docetaxel and Ramucirumab after immunochemotherapy in advanced non-small cell lung cancer patients
Japan |
Non small cell lung cac
Pneumology |
Malignancy
NO
Exploring the determinants of sensitivity to docetaxel plus ramucirumab in non-small cell lung cancer after combined immunotherapy
Safety,Efficacy
progression free survival
Observational
20 | years-old | <= |
100 | years-old | >= |
Male and Female
1) Patients aged 20 years or older with PS 0-2 at the time of obtaining consent
(2) Patients with advanced or recurrent non-small cell lung cancer that is not curatively resectable
(3) Patients with evaluable lesions by RECIST (version 1.1)
(4)Patients with a history of treatment with immune checkpoint inhibitors and chemotherapy (discontinuation due to adverse events is acceptable)
(5) Patients whose tumor PD-L1 expression is being measured using anti-22C3 antibody
(6) Patients who have been fully informed about the contents of this clinical study and have given their free written consent.
(6) Patients who have been fully informed about the contents of this clinical study and have given their free written consent.
1) Patients with a history of treatment with systemic chemotherapy after combination therapy with immune checkpoint inhibitors and chemotherapy
2) Patients with active multiple cancers (hormone therapy for prostate cancer and breast cancer is acceptable)
(3)Other patients who are deemed inappropriate by the physician in charge
50
1st name | Tadaaki |
Middle name | |
Last name | Yamada |
Kyoto Prefectural University of Medicine
Pulmonary Medicine
602-8566
465, Kajii-cho, Kamigyo-ku, Kyoto
0752515513
tayamada@koto.kpu-m.ac.jp
1st name | Yuki |
Middle name | |
Last name | Katayama |
Kyoto Prefectural University of Medicine
Pulmonary Medicine
602-8566
465, Kajii-cho, Kamigyo-ku, Kyoto
0752515513
ktym2487@koto.kpu-m.ac.jp
Kyoto Prefectural University of Medicine
None
Other
Kyoto Prefectural University of Medicine
465, Kajii-cho, Kamigyo-ku, Kyoto
0752515337
rinri@koto.kpu-m.ac.jp
NO
2021 | Year | 07 | Month | 09 | Day |
Unpublished
44
No longer recruiting
2020 | Year | 01 | Month | 05 | Day |
2020 | Year | 03 | Month | 03 | Day |
2020 | Year | 04 | Month | 01 | Day |
2022 | Year | 12 | Month | 31 | Day |
None
2021 | Year | 07 | Month | 09 | Day |
2023 | Year | 04 | Month | 26 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000050181
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |